Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C
HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genet...
Saved in:
Published in | Journal of medical virology Vol. 54; no. 4; pp. 256 - 264 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Wiley Subscription Services, Inc., A Wiley Company
01.04.1998
Wiley-Liss |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genetic variants within the quasispecies population. The genetic complexity of the HVR1 region was examined in patients with chronic hepatitis C and its relationship with the epidemiology of HCV infection, and its influence on liver disease and the response to interferon treatment were determined in 114 patients with chronic hepatitis C. The genetic complexity of the HVR1 major variants was measured before treatment by using a polymerase chain reaction (PCR)‐single‐strand conformation polymorphism (SSCP) technique, and was compared with epidemiological, clinical, virological and histological features. The patients were treated with 3 megaunits of interferon (IFN) alfa for 3 to 6 months and the response to treatment was assessed at 3, 6 and 12 months. The HVR1 could be studied in 101 of the 114 patients (89%). Genetic complexity was significantly higher in patients infected through blood transfusion than intravenous drug use (mean complexity index: 5.7 ± 2.3 vs. 4.7 ± 1.5, respectively; P = 0.04). This relationship was independent of age and the estimated time since infection. No significant relationship was found with other parameters of infection or liver disease. In univariate analysis, the genetic complexity of HVR1 major variants did not affect the rates of ALT normalization at months 3 and 6 of IFN treatment. HVR1 genetic complexity was lower in patients with a sustained virological response than in non‐responders (4.0 ± 1.7 vs. 5.4 ± 2.0, respectively; P = 0.07). In multivariate analysis of pretreatment parameters associated with a sustained virological response to treatment, three parameters appeared to be independent predictors of such a response: a low viral load (P < 0.04), a low anti‐HCV core IgM titer (P = 0.03) and a low genetic complexity of HVR1 major variants (P < 0.04). In conclusion, the HVR1 of HCV has a quasispecies distribution in infected individuals. Its genetic complexity is significantly higher in transfusion recipients than in intravenous drug users, suggesting that the size of the initial inoculum affects the later emergence and development of viral quasispecies. The genetic complexity of HVR1, together with viral load and the anti‐HCV IgM titer, are independent predictors of a sustained virological response to IFN alfa in patients with chronic hepatitis C. J. Med. Virol. 54:256–264, 1998. © 1998 Wiley‐Liss, Inc. |
---|---|
AbstractList | HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genetic variants within the quasispecies population. The genetic complexity of the HVR1 region was examined in patients with chronic hepatitis C and its relationship with the epidemiology of HCV infection, and its influence on liver disease and the response to interferon treatment were determined in 114 patients with chronic hepatitis C. The genetic complexity of the HVR1 major variants was measured before treatment by using a polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) technique, and was compared with epidemiological, clinical, virological and histological features. The patients were treated with 3 megaunits of interferon (IFN) alfa for 3 to 6 months and the response to treatment was assessed at 3, 6 and 12 months. The HVR1 could be studied in 101 of the 114 patients (89%). Genetic complexity was significantly higher in patients infected through blood transfusion than intravenous drug use (mean complexity index: 5.7 plus or minus 2.3 vs. 4.7 plus or minus 1.5, respectively; P = 0.04). This relationship was independent of age and the estimated time since infection. No significant relationship was found with other parameters of infection or liver disease. In univariate analysis, the genetic complexity of HVR1 major variants did not affect the rates of ALT normalization at months 3 and 6 of IFN treatment. HVR1 genetic complexity was lower in patients with a sustained virological response than in non-responders (4.0 plus or minus 1.7 vs. 5.4 plus or minus 2.0, respectively; P = 0.07). In multivariate analysis of pretreatment parameters associated with a sustained virological response to treatment, three parameters appeared to be independent predictors of such a response: a low viral load (P < 0.04), a low anti-HCV core IgM titer (P = 0.03) and a low genetic complexity of HVR1 major variants (P < 0.04). In conclusion, the HVR1 of HCV has a quasispecies distribution in infected individuals. Its genetic complexity is significantly higher in transfusion recipients than in intravenous drug users, suggesting that the size of the initial inoculum affects the later emergence and development of viral quasispecies. The genetic complexity of HVR1, together with viral load and the anti-HCV IgM titer, are independent predictors of a sustained virological response to IFN alfa in patients with chronic hepatitis C. HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genetic variants within the quasispecies population. The genetic complexity of the HVR1 region was examined in patients with chronic hepatitis C and its relationship with the epidemiology of HCV infection, and its influence on liver disease and the response to interferon treatment were determined in 114 patients with chronic hepatitis C. The genetic complexity of the HVR1 major variants was measured before treatment by using a polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) technique, and was compared with epidemiological, clinical, virological and histological features. The patients were treated with 3 megaunits of interferon (IFN) alfa for 3 to 6 months and the response to treatment was assessed at 3, 6 and 12 months. The HVR1 could be studied in 101 of the 114 patients (89%). Genetic complexity was significantly higher in patients infected through blood transfusion than intravenous drug use (mean complexity index: 5.7 +/- 2.3 vs. 4.7 +/- 1.5, respectively; P = 0.04). This relationship was independent of age and the estimated time since infection. No significant relationship was found with other parameters of infection or liver disease. In univariate analysis, the genetic complexity of HVR1 major variants did not affect the rates of ALT normalization at months 3 and 6 of IFN treatment. HVR1 genetic complexity was lower in patients with a sustained virological response than in non-responders (4.0 +/- 1.7 vs. 5.4 +/- 2.0, respectively; P = 0.07). In multivariate analysis of pretreatment parameters associated with a sustained virological response to treatment, three parameters appeared to be independent predictors of such a response: a low viral load (P < 0.04), a low anti-HCV core IgM titer (P = 0.03) and a low genetic complexity of HVR1 major variants (P < 0.04). In conclusion, the HVR1 of HCV has a quasispecies distribution in infected individuals. Its genetic complexity is significantly higher in transfusion recipients than in intravenous drug users, suggesting that the size of the initial inoculum affects the later emergence and development of viral quasispecies. The genetic complexity of HVR1, together with viral load and the anti-HCV IgM titer, are independent predictors of a sustained virological response to IFN alfa in patients with chronic hepatitis. HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genetic variants within the quasispecies population. The genetic complexity of the HVR1 region was examined in patients with chronic hepatitis C and its relationship with the epidemiology of HCV infection, and its influence on liver disease and the response to interferon treatment were determined in 114 patients with chronic hepatitis C. The genetic complexity of the HVR1 major variants was measured before treatment by using a polymerase chain reaction (PCR)‐single‐strand conformation polymorphism (SSCP) technique, and was compared with epidemiological, clinical, virological and histological features. The patients were treated with 3 megaunits of interferon (IFN) alfa for 3 to 6 months and the response to treatment was assessed at 3, 6 and 12 months. The HVR1 could be studied in 101 of the 114 patients (89%). Genetic complexity was significantly higher in patients infected through blood transfusion than intravenous drug use (mean complexity index: 5.7 ± 2.3 vs. 4.7 ± 1.5, respectively; P = 0.04). This relationship was independent of age and the estimated time since infection. No significant relationship was found with other parameters of infection or liver disease. In univariate analysis, the genetic complexity of HVR1 major variants did not affect the rates of ALT normalization at months 3 and 6 of IFN treatment. HVR1 genetic complexity was lower in patients with a sustained virological response than in non‐responders (4.0 ± 1.7 vs. 5.4 ± 2.0, respectively; P = 0.07). In multivariate analysis of pretreatment parameters associated with a sustained virological response to treatment, three parameters appeared to be independent predictors of such a response: a low viral load (P < 0.04), a low anti‐HCV core IgM titer (P = 0.03) and a low genetic complexity of HVR1 major variants (P < 0.04). In conclusion, the HVR1 of HCV has a quasispecies distribution in infected individuals. Its genetic complexity is significantly higher in transfusion recipients than in intravenous drug users, suggesting that the size of the initial inoculum affects the later emergence and development of viral quasispecies. The genetic complexity of HVR1, together with viral load and the anti‐HCV IgM titer, are independent predictors of a sustained virological response to IFN alfa in patients with chronic hepatitis C. J. Med. Virol. 54:256–264, 1998. © 1998 Wiley‐Liss, Inc. HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genetic variants within the quasispecies population. The genetic complexity of the HVR1 region was examined in patients with chronic hepatitis C and its relationship with the epidemiology of HCV infection, and its influence on liver disease and the response to interferon treatment were determined in 114 patients with chronic hepatitis C. The genetic complexity of the HVR1 major variants was measured before treatment by using a polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) technique, and was compared with epidemiological, clinical, virological and histological features. The patients were treated with 3 megaunits of interferon (IFN) alfa for 3 to 6 months and the response to treatment was assessed at 3, 6 and 12 months. The HVR1 could be studied in 101 of the 114 patients (89%). Genetic complexity was significantly higher in patients infected through blood transfusion than intravenous drug use (mean complexity index: 5.7 +/- 2.3 vs. 4.7 +/- 1.5, respectively; P = 0.04). This relationship was independent of age and the estimated time since infection. No significant relationship was found with other parameters of infection or liver disease. In univariate analysis, the genetic complexity of HVR1 major variants did not affect the rates of ALT normalization at months 3 and 6 of IFN treatment. HVR1 genetic complexity was lower in patients with a sustained virological response than in non-responders (4.0 +/- 1.7 vs. 5.4 +/- 2.0, respectively; P = 0.07). In multivariate analysis of pretreatment parameters associated with a sustained virological response to treatment, three parameters appeared to be independent predictors of such a response: a low viral load (P < 0.04), a low anti-HCV core IgM titer (P = 0.03) and a low genetic complexity of HVR1 major variants (P < 0.04). In conclusion, the HVR1 of HCV has a quasispecies distribution in infected individuals. Its genetic complexity is significantly higher in transfusion recipients than in intravenous drug users, suggesting that the size of the initial inoculum affects the later emergence and development of viral quasispecies. The genetic complexity of HVR1, together with viral load and the anti-HCV IgM titer, are independent predictors of a sustained virological response to IFN alfa in patients with chronic hepatitis. |
Author | Bouvier, Magali Soussy, Claude-James Pawlotsky, Jean-Michel Dhumeaux, Daniel Roudot-Thoraval, Françoise Pellerin, Muriel Bastie, Anne Rémiré, Jocelyne Germanidis, Georgios Darthuy, Françoise |
Author_xml | – sequence: 1 givenname: Jean-Michel surname: Pawlotsky fullname: Pawlotsky, Jean-Michel organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France – sequence: 2 givenname: Muriel surname: Pellerin fullname: Pellerin, Muriel organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France – sequence: 3 givenname: Magali surname: Bouvier fullname: Bouvier, Magali organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France – sequence: 4 givenname: Françoise surname: Roudot-Thoraval fullname: Roudot-Thoraval, Françoise organization: Department of Epidemiology, Hôpital Henri Mondor, Université Paris XII, Créteil, France – sequence: 5 givenname: Georgios surname: Germanidis fullname: Germanidis, Georgios organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France – sequence: 6 givenname: Anne surname: Bastie fullname: Bastie, Anne organization: Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Université Paris XII, Créteil, France – sequence: 7 givenname: Françoise surname: Darthuy fullname: Darthuy, Françoise organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France – sequence: 8 givenname: Jocelyne surname: Rémiré fullname: Rémiré, Jocelyne organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France – sequence: 9 givenname: Claude-James surname: Soussy fullname: Soussy, Claude-James organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France – sequence: 10 givenname: Daniel surname: Dhumeaux fullname: Dhumeaux, Daniel organization: Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Université Paris XII, Créteil, France |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2258420$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9557291$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUt1u0zAYjdDQ6AaPgOQLhNqLDP_FScqENAX6gwaVxijcfXIchxrSJNjptj4nL4RDS0ECaVeWfY7POfq-cxIc1U2tg-Cc4DOCMX0x_DDP5iOCUxGmOCZDkqYJ5qOIj_k5jcR4fDF_Hb59t-Sv2Bk-yxYvacgeBIPDh6NggAkXoRAkehScOPcVY5yklB4Hx2kUxTQlg-DHVNe6MwqpZt1W-s50W9SUqFtptNq22t5Ia2ReaWT1F9PUiKDhbHlFRj1ppVvZmc44lKEbYzfOY9lyNEbzuqw2ulYa-R-9lFpJK1WnrXHey_12MHWpVdfLyrrwDq5taqcd6hoPeXapbY9VpezpVrZb_456U113Dt2abuWlPcfn_yvM4-BhKSunn-zP0-Dj5M11NgsvF9N5dnEZKhYzHhZ5LpSOEhzTQgosmCxSmUjOc-lHWJIiViKnqowjISUXUkRxXhRY4aTAnBYJOw2e73Rb23zfaNfB2jilq0rWutk4iNOEUD_8e4lEsJTRRHji9Y6obOOc1SW01qyl3QLB0JcCoC8F9DuGfsewKwVEHDj4UgD4UkBfCmCAIVsABeZln-79N_laFwfRfQs8_myPS6f8uK2slXEHGqVRwin-k-7WVHr7T7R7kv0n2K-7lw13sr4c-u4gK-03EDGLI_j0fgqfGcOT2VUCE_YTRmPyaA |
CODEN | JMVIDB |
Cites_doi | 10.1002/hep.510240507 10.1128/AAC.40.2.320 10.1128/JVI.66.5.3225-3229.1992 10.1182/blood.V85.7.1681.bloodjournal8571681 10.1073/pnas.91.16.7792 10.7326/0003-4819-122-3-199502010-00002 10.1099/0022-1317-75-6-1361 10.1099/0022-1317-74-6-1093 10.1002/hep.1840200605 10.1002/hep.1840160302 10.1056/NEJM198612183152503 10.1002/hep.1840200504 10.1056/NEJM198911303212202 10.1016/0888-7543(89)90129-8 10.1128/JCM.33.7.1870-1874.1995 10.1099/0022-1317-76-7-1763 10.1002/(SICI)1096-9071(199607)49:3<242::AID-JMV14>3.0.CO;2-E 10.1099/0022-1317-76-4-881 10.1128/JCM.32.5.1357-1359.1994 10.1016/0016-5085(95)90452-2 10.1093/infdis/171.6.1607 10.1016/0168-8278(90)90075-3 10.7326/0003-4819-123-8-199510150-00008 10.1073/pnas.89.8.3468 10.1007/978-3-642-77011-1_1 10.1001/archderm.1995.01690220091017 10.1002/jmv.1890460103 10.1093/infdis/171.6.1619 10.1093/infdis/174.1.1 10.1002/hep.1840220406 10.1016/0016-5085(94)90770-6 10.1016/0027-5107(93)90209-X 10.1073/pnas.91.11.4821 10.1128/JCM.34.4.901-907.1996 |
ContentType | Journal Article |
Copyright | Copyright © 1998 Wiley‐Liss, Inc. 1998 INIST-CNRS |
Copyright_xml | – notice: Copyright © 1998 Wiley‐Liss, Inc. – notice: 1998 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U9 8FD FR3 H94 P64 RC3 7X8 |
DOI | 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3 |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts Genetics Abstracts Virology and AIDS Abstracts Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1096-9071 |
EndPage | 264 |
ExternalDocumentID | 10_1002__SICI_1096_9071_199804_54_4_256__AID_JMV4_3_0_CO_2_3 9557291 2258420 JMV4 ark_67375_WNG_X330FHR8_F |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3O- 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAVGM AAXRX AAZKR ABCQN ABCUV ABEML ABHUG ABIJN ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXME ACXQS ADAWD ADBBV ADBTR ADDAD ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEQTP AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFVGU AFZJQ AGJLS AHBTC AHMBA AI. AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS ECGQY EJD ELTNK EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E VH1 W8V W99 WBKPD WHG WIB WIH WIJ WIK WJL WNSPC WOHZO WQJ WRC WUP WXI WXSBR WYISQ X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~KM ~WT AITYG HGLYW OIG 08R AAUGY IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U9 8FD FR3 H94 P64 RC3 7X8 |
ID | FETCH-LOGICAL-c3734-dbb6ce58072da6063ad9a8a44ba096f1d7c6b2cf756aa46a657bdd0c08d042d83 |
IEDL.DBID | DR2 |
ISSN | 0146-6615 |
IngestDate | Fri Aug 16 21:51:00 EDT 2024 Sat Aug 17 03:21:23 EDT 2024 Fri Aug 23 00:17:44 EDT 2024 Sat Sep 28 07:40:28 EDT 2024 Sun Oct 29 17:09:53 EDT 2023 Sat Aug 24 00:56:13 EDT 2024 Wed Jan 17 04:59:33 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Human Genetic variability RNA Alpha interferon Cytokine Hepatic disease Hypervariable region Infection Virus Chemotherapy Treatment Viral disease Molecular epidemiology Digestive diseases Antiviral Flaviviridae Hepatitis C virus Hepacivirus Viral hepatitis C |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3734-dbb6ce58072da6063ad9a8a44ba096f1d7c6b2cf756aa46a657bdd0c08d042d83 |
Notes | ArticleID:JMV4 istex:A836BC00AED8147B42C0DE9C0574D063B8E03786 ark:/67375/WNG-X330FHR8-F ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 9557291 |
PQID | 16393286 |
PQPubID | 23462 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_79812615 proquest_miscellaneous_16393286 crossref_primary_10_1002__SICI_1096_9071_199804_54_4_256__AID_JMV4_3_0_CO_2_3 pubmed_primary_9557291 pascalfrancis_primary_2258420 wiley_primary_10_1002_SICI_1096_9071_199804_54_4_256_AID_JMV4_3_0_CO_2_3_JMV4 istex_primary_ark_67375_WNG_X330FHR8_F |
PublicationCentury | 1900 |
PublicationDate | April 1998 |
PublicationDateYYYYMMDD | 1998-04-01 |
PublicationDate_xml | – month: 04 year: 1998 text: April 1998 |
PublicationDecade | 1990 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: New York, NY – name: United States |
PublicationTitle | Journal of medical virology |
PublicationTitleAlternate | J. Med. Virol |
PublicationYear | 1998 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
References | Gumber SC, Chopra S: (1995): Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Annals of Internal Medicine 123: 615-620. Pawlotsky JM, Fleury A, Choukroun V, Deforges L, Roudot-Thoraval F, Aumont P, Duval J, Dhumeaux D: (1994): Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA. Journal of Clinical Microbiology 32: 1357-1359. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou JP, Erlinger S: (1995): Pretreatment HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 22: 1050-1056. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Kamada T: (1994): Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 20: 1121-1130. Pawlotsky JM, Roudot-Thoraval F, Bastie A, Darthuy F, Rémiré J, Métreau JM, Zafrani ES, Duval J, Dhumeaux D: (1996b): Factors affecting treatment responses to interferon-a in chronic hepatitis C. Journal of Infectious Diseases 174: 1-7. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, DiBisceglie AM, Peters M, Waggoner JG, Park Y, Jones EA: (1986): Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. New England Journal of Medicine 315: 1575-1578. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C: (1995): Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 22: 30-35. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D: (1995c): Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. Journal of Infectious Diseases 171: 1607-1610. Orita M, Suzuki Y, Sekiya T, Hayashi K: (1989): Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879. Mahaney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, Hoofnagle JH, Sallie R: (1994): Genotypic analysis of hepatitis C virus in American patients. Hepatology 20: 1405-1411. Pawlotsky JM, Hovanessian AG, Roudot-Thoraval F, Robert N, Bou-vier M, Babany G, Duval J, Dhumeaux D: (1996a): Effect of alpha interferon (IFN-a) on 2′-5′ oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-a. Antimicrobial Agents and Chemotherapy 40: 320-324. Holland JJ, De La Torre JC, Steinhauer DA: (1992): RNA virus populations as quasispecies. Current Topics in Microbiology and Immunology 176: 1-20. Lu M, Funsch B, Wiese M, Roggendorf M: (1995): Analysis of hepatitis C virus quasispecies populations by temperature gradient gel electrophoresis. Journal of General Virology 76: 881-887. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, Mellor J, Yahia M Ben, André C, Voisin MC, Intrator L, Zafrani ES, Duval J, Dhumeaux D: (1995b): Extra-hepatic immunological manifestations in chronic hepatitis C and hepatitis C virus serotypes. Annals of Internal Medicine 122: 169-173. Duarte EA, Novella IS, Weaver SC, Domingo E, Wain-Hobson S, Clarke DK, Moya A, Elena SF, de la Torre JC, Holland JJ: (1994): RNA virus quasispecies: significance for viral disease and epidemiology. Infectious Agents and Disease 3: 201-214. Odeberg J, Yun Z, Sönnerborg A, Uhlen M, Lundeberg J: (1995): Dynamic analysis of heterogeneous hepatitis C virus populations by direct solid-phase sequencing. Journal of Clinical Microbiology 33: 1870-1874. Alter HJ: (1995): To C or not to C: these are the questions. Blood 85: 1681-1695. Hopf U, Möller B, Küther D, Stemerowicz R, Lobeck H, Lüdtke-Handjery, Walter E, Blum HE, Roggendorf M, Deinhardt F: (1990): Long term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). Journal of Hepatology 10: 69-76. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J: (1992): Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCgenome distribution. Journal of Virology 66: 3225-29. Sekiya T: (1993): Detection of mutant sequences by single-strand conformation polymorphism analysis. Mutation Research 288: 79-83. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G: (1989): Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. New England Journal of Medicine 321: 1494-1500. Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T: (1996): The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. Hepatology 24: 1018-1023. Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S: (1992): The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16: 619-624. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, Purcell RH: (1994): Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proceedings of the National Academy of Sciences USA 91: 7792-7796. Lin HJ, Siwak EB, Lauder IJ, Hollinger FB: (1995): Single-strand conformation polymorphism study of human immunodeficiency virus type 1 RNA and DNA in plasma, peripheral blood mononuclear cells, and their virologic cultures. Journal of Infectious Diseases 171: 1619-1622. Weiner AJ, Geysem HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA, Brunetto M, Barr PJ, Miyamura T, McHutchison J, Houghton M: (1992): Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants : potential role in chronic HCV infections. Proceedings of the National Academy of Sciences (USA) 89: 3468-3472. Clarke DK, Duarte EA, Elena SF, Moya A, Domingo E, Holland J: (1994): The red queen reigns in the kingdom of RNA viruses. Proceedings of the National Academy of Sciences (USA) 91: 4821-4824. Wilson JJ, Polyak SJ, Day TD, Gretch DR: (1995): Characterization of simple and complex hepatitis C virus quasispecies by heteroduplex gel shift analysis: correlation with nucleotide sequencing. Journal of General Virology 76: 1763-1771. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C: (1994): Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. Journal of General Virology 75: 1361-1369. Pawlotsky JM, Dhumeaux D, Bagot M: (1995a) Hepatitis C virus in dermatology. A review. Archives of Dermatology 131: 1185-1193. Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, Urdea M, Sanchez-Pescador R: (1996): Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. Journal of Clinical Microbiology 34: 901-907. Gonzalez-Peralta RP, Qian KP, She JY, Davis GL, Ohno T, Mizokami M, Lau JYN: (1996): Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. Journal of Medical Virology 49: 242-247. Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, Kaneshige T, Igimi H, Kamada T, Uchida K: (1995): Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 108: 789-795. Sakamoto N, Enomoto N, Kurosaki M, Asahina Y, Maekawa S, Koizumi K, Sakuma I, Murakami T, Marumo F, Sato C: (1995): Comparison of the hypervariable region of hepatitis C virus genomes in plasma and liver. Journal of Medical Virology 46: 7-11. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, van Heuverswyn H, Maertens G: (1993): Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. Journal of General Virology 74: 1093-1102. Kumar U, Monjardino J, Thomas HC: (1994): Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 106: 1072-1075. 1995a; 131 1986; 315 1989; 5 1990; 10 1996b; 174 1995b; 122 1995; 33 1995; 76 1997 1992; 16 1995; 171 1996; 34 1993; 288 1994; 20 1995; 85 1994; 106 1989; 321 1992; 176 1996a; 40 1995; 46 1995; 22 1995; 108 1993; 74 1995c; 171 1995; 123 1994; 91 1996; 24 1994; 3 1996; 49 1992; 66 1992; 89 1994; 32 1988 1994; 75 Detmer (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB4) 1996; 34 Hopf (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB14) 1990; 10 Martell (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB21) 1992; 66 Clarke (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB3) 1994; 91 Holland (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB12) 1992; 176 Urdea (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB37) 1997 Martinot-Peignoux (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB22) 1995; 22 Sakamoto (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB33) 1995; 46 Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB27) 1995a; 131 Weiner (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB38) 1992; 89 Kumar (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB17) 1994; 106 Odeberg (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB24) 1995; 33 Lin (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB18) 1995; 171 Enomoto (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB7) 1994; 75 Mahaney (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB20) 1994; 20 Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB29) 1996a; 40 Wilson (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB39) 1995; 76 Alter (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB2) 1995; 85 Eigen (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB6) 1988 Sekiya (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB34) 1993; 288 Kanazawa (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB15) 1994; 20 Okada (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB25) 1992; 16 Gonzalez-Peralta (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB9) 1996; 49 Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB31) 1995b; 122 Hoofnagle (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB13) 1986; 315 Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB30) 1996b; 174 Lu (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB19) 1995; 76 Orita (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB26) 1989; 5 Koizumi (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB16) 1995; 22 Farci (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB8) 1994; 91 Shindo (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB35) 1996; 24 Moribe (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB23) 1995; 108 Gretch (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB10) 1997 Stuyver (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB36) 1993; 74 Alter (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB1) 1989; 321 Gumber (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB11) 1995; 123 Duarte (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB5) 1994; 3 Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB28) 1994; 32 Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB32) 1995c; 171 |
References_xml | – volume: 20 start-page: 1405 year: 1994 end-page: 1411 article-title: Genotypic analysis of hepatitis C virus in American patients publication-title: Hepatology – volume: 20 start-page: 1121 year: 1994 end-page: 1130 article-title: Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients publication-title: Hepatology – volume: 321 start-page: 1494 year: 1989 end-page: 1500 article-title: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non‐A, non‐B hepatitis publication-title: New England Journal of Medicine – volume: 34 start-page: 901 year: 1996 end-page: 907 article-title: Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched‐DNA technology publication-title: Journal of Clinical Microbiology – volume: 76 start-page: 1763 year: 1995 end-page: 1771 article-title: Characterization of simple and complex hepatitis C virus quasispecies by heteroduplex gel shift analysis: correlation with nucleotide sequencing publication-title: Journal of General Virology – volume: 315 start-page: 1575 year: 1986 end-page: 1578 article-title: Treatment of chronic non‐A, non‐B hepatitis with recombinant human alpha interferon. A preliminary report publication-title: New England Journal of Medicine – start-page: 73 year: 1997 end-page: 78 – start-page: 57 year: 1997 end-page: 69 – volume: 22 start-page: 1050 year: 1995 end-page: 1056 article-title: Pretreatment HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C publication-title: Hepatology – volume: 10 start-page: 69 year: 1990 end-page: 76 article-title: Long term follow‐up of posttransfusion and sporadic chronic hepatitis non‐A, non‐B and frequency of circulating antibodies to hepatitis C virus (HCV) publication-title: Journal of Hepatology – volume: 49 start-page: 242 year: 1996 end-page: 247 article-title: Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C publication-title: Journal of Medical Virology – volume: 76 start-page: 881 year: 1995 end-page: 887 article-title: Analysis of hepatitis C virus quasispecies populations by temperature gradient gel electrophoresis publication-title: Journal of General Virology – volume: 85 start-page: 1681 year: 1995 end-page: 1695 article-title: To C or not to C: these are the questions publication-title: Blood – volume: 106 start-page: 1072 year: 1994 end-page: 1075 article-title: Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient publication-title: Gastroenterology – volume: 46 start-page: 7 year: 1995 end-page: 11 article-title: Comparison of the hypervariable region of hepatitis C virus genomes in plasma and liver publication-title: Journal of Medical Virology – volume: 33 start-page: 1870 year: 1995 end-page: 1874 article-title: Dynamic analysis of heterogeneous hepatitis C virus populations by direct solid‐phase sequencing publication-title: Journal of Clinical Microbiology – volume: 16 start-page: 619 year: 1992 end-page: 624 article-title: The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients publication-title: Hepatology – volume: 32 start-page: 1357 year: 1994 end-page: 1359 article-title: Significance of highly positive c22‐3 “indeterminate” second‐generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third‐generation HCV RIBA publication-title: Journal of Clinical Microbiology – volume: 24 start-page: 1018 year: 1996 end-page: 1023 article-title: The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy publication-title: Hepatology – volume: 171 start-page: 1607 year: 1995c end-page: 1610 article-title: Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C publication-title: Journal of Infectious Diseases – volume: 75 start-page: 1361 year: 1994 end-page: 1369 article-title: Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single‐strand conformation polymorphism analysis publication-title: Journal of General Virology – volume: 288 start-page: 79 year: 1993 end-page: 83 article-title: Detection of mutant sequences by single‐strand conformation polymorphism analysis publication-title: Mutation Research – volume: 91 start-page: 7792 year: 1994 end-page: 7796 article-title: Prevention of hepatitis C virus infection in chimpanzees after antibody‐mediated in vitro neutralization publication-title: Proceedings of the National Academy of Sciences USA – volume: 176 start-page: 1 year: 1992 end-page: 20 article-title: RNA virus populations as quasispecies publication-title: Current Topics in Microbiology and Immunology – volume: 3 start-page: 201 year: 1994 end-page: 214 article-title: RNA virus quasispecies: significance for viral disease and epidemiology publication-title: Infectious Agents and Disease – volume: 40 start-page: 320 year: 1996a end-page: 324 article-title: Effect of alpha interferon (IFN‐a) on 2′‐5′ oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN‐a publication-title: Antimicrobial Agents and Chemotherapy – volume: 22 start-page: 30 year: 1995 end-page: 35 article-title: Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment publication-title: Hepatology – volume: 89 start-page: 3468 year: 1992 end-page: 3472 article-title: Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants : potential role in chronic HCV infections publication-title: Proceedings of the National Academy of Sciences (USA) – volume: 122 start-page: 169 year: 1995b end-page: 173 article-title: Extra‐hepatic immunological manifestations in chronic hepatitis C and hepatitis C virus serotypes publication-title: Annals of Internal Medicine – volume: 91 start-page: 4821 year: 1994 end-page: 4824 article-title: The red queen reigns in the kingdom of RNA viruses publication-title: Proceedings of the National Academy of Sciences (USA) – volume: 174 start-page: 1 year: 1996b end-page: 7 article-title: Factors affecting treatment responses to interferon‐a in chronic hepatitis C publication-title: Journal of Infectious Diseases – volume: 74 start-page: 1093 year: 1993 end-page: 1102 article-title: Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay publication-title: Journal of General Virology – volume: 171 start-page: 1619 year: 1995 end-page: 1622 article-title: Single‐strand conformation polymorphism study of human immunodeficiency virus type 1 RNA and DNA in plasma, peripheral blood mononuclear cells, and their virologic cultures publication-title: Journal of Infectious Diseases – volume: 108 start-page: 789 year: 1995 end-page: 795 article-title: Hepatitis C viral complexity detected by single‐strand conformation polymorphism and response to interferon therapy publication-title: Gastroenterology – start-page: 211 year: 1988 end-page: 245 – volume: 5 start-page: 874 year: 1989 end-page: 879 article-title: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction publication-title: Genomics – volume: 131 start-page: 1185 year: 1995a end-page: 1193 article-title: Hepatitis C virus in dermatology. A review publication-title: Archives of Dermatology – volume: 123 start-page: 615 year: 1995 end-page: 620 article-title: Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations publication-title: Annals of Internal Medicine – volume: 66 start-page: 3225 year: 1992 end-page: 29 article-title: Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCgenome distribution publication-title: Journal of Virology – volume: 24 start-page: 1018 year: 1996 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB35 publication-title: Hepatology doi: 10.1002/hep.510240507 contributor: fullname: Shindo – volume: 3 start-page: 201 year: 1994 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB5 publication-title: Infectious Agents and Disease contributor: fullname: Duarte – volume: 40 start-page: 320 year: 1996a ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB29 publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.40.2.320 contributor: fullname: Pawlotsky – volume: 66 start-page: 3225 year: 1992 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB21 publication-title: Journal of Virology doi: 10.1128/JVI.66.5.3225-3229.1992 contributor: fullname: Martell – volume: 85 start-page: 1681 year: 1995 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB2 publication-title: Blood doi: 10.1182/blood.V85.7.1681.bloodjournal8571681 contributor: fullname: Alter – volume: 91 start-page: 7792 year: 1994 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB8 publication-title: Proceedings of the National Academy of Sciences USA doi: 10.1073/pnas.91.16.7792 contributor: fullname: Farci – volume: 122 start-page: 169 year: 1995b ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB31 publication-title: Annals of Internal Medicine doi: 10.7326/0003-4819-122-3-199502010-00002 contributor: fullname: Pawlotsky – volume: 75 start-page: 1361 year: 1994 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB7 publication-title: Journal of General Virology doi: 10.1099/0022-1317-75-6-1361 contributor: fullname: Enomoto – volume: 74 start-page: 1093 year: 1993 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB36 publication-title: Journal of General Virology doi: 10.1099/0022-1317-74-6-1093 contributor: fullname: Stuyver – volume: 20 start-page: 1405 year: 1994 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB20 publication-title: Hepatology doi: 10.1002/hep.1840200605 contributor: fullname: Mahaney – volume: 16 start-page: 619 year: 1992 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB25 publication-title: Hepatology doi: 10.1002/hep.1840160302 contributor: fullname: Okada – volume: 315 start-page: 1575 year: 1986 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB13 publication-title: New England Journal of Medicine doi: 10.1056/NEJM198612183152503 contributor: fullname: Hoofnagle – volume: 20 start-page: 1121 year: 1994 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB15 publication-title: Hepatology doi: 10.1002/hep.1840200504 contributor: fullname: Kanazawa – volume: 321 start-page: 1494 year: 1989 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB1 publication-title: New England Journal of Medicine doi: 10.1056/NEJM198911303212202 contributor: fullname: Alter – volume: 5 start-page: 874 year: 1989 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB26 publication-title: Genomics doi: 10.1016/0888-7543(89)90129-8 contributor: fullname: Orita – volume: 33 start-page: 1870 year: 1995 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB24 publication-title: Journal of Clinical Microbiology doi: 10.1128/JCM.33.7.1870-1874.1995 contributor: fullname: Odeberg – volume: 76 start-page: 1763 year: 1995 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB39 publication-title: Journal of General Virology doi: 10.1099/0022-1317-76-7-1763 contributor: fullname: Wilson – volume: 49 start-page: 242 year: 1996 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB9 publication-title: Journal of Medical Virology doi: 10.1002/(SICI)1096-9071(199607)49:3<242::AID-JMV14>3.0.CO;2-E contributor: fullname: Gonzalez-Peralta – volume: 76 start-page: 881 year: 1995 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB19 publication-title: Journal of General Virology doi: 10.1099/0022-1317-76-4-881 contributor: fullname: Lu – volume: 32 start-page: 1357 year: 1994 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB28 publication-title: Journal of Clinical Microbiology doi: 10.1128/JCM.32.5.1357-1359.1994 contributor: fullname: Pawlotsky – volume: 108 start-page: 789 year: 1995 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB23 publication-title: Gastroenterology doi: 10.1016/0016-5085(95)90452-2 contributor: fullname: Moribe – volume: 22 start-page: 30 year: 1995 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB16 publication-title: Hepatology contributor: fullname: Koizumi – volume: 171 start-page: 1607 year: 1995c ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB32 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/171.6.1607 contributor: fullname: Pawlotsky – volume: 10 start-page: 69 year: 1990 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB14 publication-title: Journal of Hepatology doi: 10.1016/0168-8278(90)90075-3 contributor: fullname: Hopf – volume: 123 start-page: 615 year: 1995 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB11 publication-title: Annals of Internal Medicine doi: 10.7326/0003-4819-123-8-199510150-00008 contributor: fullname: Gumber – volume: 89 start-page: 3468 year: 1992 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB38 publication-title: Proceedings of the National Academy of Sciences (USA) doi: 10.1073/pnas.89.8.3468 contributor: fullname: Weiner – volume: 176 start-page: 1 year: 1992 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB12 publication-title: Current Topics in Microbiology and Immunology doi: 10.1007/978-3-642-77011-1_1 contributor: fullname: Holland – start-page: 73 volume-title: Hepatitis C virus: genetic heterogeneity and viral load year: 1997 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB37 contributor: fullname: Urdea – start-page: 211 volume-title: RNA genetics, Volume 3: Variability of RNA Genomes year: 1988 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB6 contributor: fullname: Eigen – start-page: 57 volume-title: Hepatitis C Virus: Genetic Heterogeneity and Viral Load year: 1997 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB10 contributor: fullname: Gretch – volume: 131 start-page: 1185 year: 1995a ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB27 publication-title: Archives of Dermatology doi: 10.1001/archderm.1995.01690220091017 contributor: fullname: Pawlotsky – volume: 46 start-page: 7 year: 1995 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB33 publication-title: Journal of Medical Virology doi: 10.1002/jmv.1890460103 contributor: fullname: Sakamoto – volume: 171 start-page: 1619 year: 1995 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB18 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/171.6.1619 contributor: fullname: Lin – volume: 174 start-page: 1 year: 1996b ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB30 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/174.1.1 contributor: fullname: Pawlotsky – volume: 22 start-page: 1050 year: 1995 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB22 publication-title: Hepatology doi: 10.1002/hep.1840220406 contributor: fullname: Martinot-Peignoux – volume: 106 start-page: 1072 year: 1994 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB17 publication-title: Gastroenterology doi: 10.1016/0016-5085(94)90770-6 contributor: fullname: Kumar – volume: 288 start-page: 79 year: 1993 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB34 publication-title: Mutation Research doi: 10.1016/0027-5107(93)90209-X contributor: fullname: Sekiya – volume: 91 start-page: 4821 year: 1994 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB3 publication-title: Proceedings of the National Academy of Sciences (USA) doi: 10.1073/pnas.91.11.4821 contributor: fullname: Clarke – volume: 34 start-page: 901 year: 1996 ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB4 publication-title: Journal of Clinical Microbiology doi: 10.1128/JCM.34.4.901-907.1996 contributor: fullname: Detmer |
SSID | ssj0008922 |
Score | 1.9115201 |
Snippet | HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is... |
SourceID | proquest crossref pubmed pascalfrancis wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 256 |
SubjectTerms | Adolescent Adult Aged Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use Base Sequence Biological and medical sciences Female genetic complexity Genetic Variation Hepacivirus - drug effects Hepacivirus - genetics hepatitis C virus Hepatitis C, Chronic - drug therapy Human viral diseases Humans hypervariable region 1 Infectious diseases interferon alpha Interferon-alpha - therapeutic use Male Medical sciences Middle Aged Molecular Sequence Data Pharmacology. Drug treatments Polymerase Chain Reaction Polymorphism, Single-Stranded Conformational quasispecies Sequence Alignment Sequence Homology, Nucleic Acid Viral diseases Viral Envelope Proteins - genetics Viral hepatitis |
Title | Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C |
URI | https://api.istex.fr/ark:/67375/WNG-X330FHR8-F/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2F%28SICI%291096-9071%28199804%2954%3A4%3C256%3A%3AAID-JMV4%3E3.0.CO%3B2-3 https://www.ncbi.nlm.nih.gov/pubmed/9557291 https://search.proquest.com/docview/16393286 https://search.proquest.com/docview/79812615 |
Volume | 54 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1fb9MwELemIU288H-iwMAPDLUP6ZLYiZMyIY2w0k7qJhXW9c1yYkerhlLUtGjsq_Cx-ELcxU1HYYgXJKRWav75at_Zvl989zMhL02cA65QxlFeoB0ec89RLAwdVWVhZrERGnOHB8dh75QfjYPxBrmqc2EsP8TqhRv2jGq8xg6u0nLvmjQUHLAP_aQPgNkDN9wBkOchtRHAB5fv4uoVqBi-Cczp8As-B_13ztFgBOcOWdttJye77K3vIFEo8vChPzW8Zp6KYrsAAQOJA1NYsEX2l6L3mii2tRLatCJbAe_wfRDW6dSC3lgxr0HI2qx3CxV4iVGYqgRF5HYHjZtc3HWPuZryunfJt7qxbKTLRXsxT9vZ1S88kv-nNe-RO0tPmh5Y079PNkzxgGwNlrECD8l3ZNSGa7SKmjeXADfoNKfg8NJzAN-4JdIE88Yo7k0xLahHm73R0GvhTecGA83nk5Im9MtktijhWjJqdWi_3tOFwhNYVLZOeF1LqGPcCqoKDRKqQGRT0vmUIkHHLDczvPYpV9RmwH2F83RJcltSfDsORVe8xT__mUfktHv4Mek5yy0snIwJxh2dpmFmgsgVvlaAFZnSsYoU56mCZs49LbIw9bNcBKFSPFRhIFKt3cyNNIymOmLbZLOYFuYxoUzHWvk8M64WPAfUGvuREkyLHLqVFmGDDGoTk58tU4m0nNS-lKhbDDYIJWpWWr3KgEsuQaNSgjYlalMy6crkRPqSNciryk5XhanZBUYBikCeHb-XY8bcbm8YyW6D7KwZ8uoBmCoi7rsN8qI2bAljFy5IqcJMF6UELADwIQr_fIeIwQGF7tcg27ZHrAqPgwBwoQe1rsz6tyr_pcY3VLg6fvKPy3tKbtssVoz1ekY257OF2QE3dp4-rwacH-5Hf1w |
link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1fb9MwELfGJg1e-D9RYMwPDLUP6ZLY-VcmpJGttGPtpLGVvllO7GjVUIqaFg34KnwrvhB3cdNRGOIFCamVmjjx1T7f-c6--5mQ5zrKwK-Q2pKOpywecceSzPctWWZhppEOFOYO9_p-54wfDr3hCvla5cIYfIjFghtKRqmvUcBxQXrnCjUULLB33bgLHrMDdrgFXp6D2EbgP9h8G7evgMfwjWFSh1_w2evuW4e9Adw7YE27GR9vs9euxW6QNdAWHkr1_skV9lQYmS0IUCUWTGLeOtmd096pI93Ggmrd0Gx4vMV3gVqrVVF6Zei8BCpL894asvAS4zBlAazIzBka1xm5yzZzOem175BvVXeZWJeL5myaNNMvvyBJ_qf-vEtuz41pumdG_z2yovP7ZL03Dxd4QL4jqDaU0TJwXl-Cx0HHGQWbl56D_42nIo0wdYzi8RTjnDq03hmcOA186FxjrPl0VNCYfhpNZgWUxYNGi3arY10ovIFVpcuY1xWFKswtpzJXQKGMRdYFnY4pYnRMMj3Bsg-ZpCYJ7jPcp3Oc24LiAjlUXUIX__xnHpKz9sFp3LHmp1hYKQsYt1SS-Kn2QjtwlQR3kUkVyVBynkjo5sxRQeonbpoFni8l96XvBYlSdmqHChSqCtkGWc3HuX5EKFORki5Pta0CnoHjGrmhDJgKMpAsFfg10qvGmPhowEqEgaV2hUDeYryBL5CzwvBVeFxwARwVArgpkJuCCVvEx8IVrEZelAN1UZmcXGAgYOCJ9_03YsiY3e6chKJdI5tLI3nxAswWIXftGtmqRrYA9YV7UjLX41khwB0ADyL0__xEEIENCvJXIxtGJBaVR54HrqEDrS7H9W9N_kuLr2lwef34H9e3RW52TntH4qjbf_uE3DJJrRj69ZSsTiczvQlW7TR5VmqfH_Epg3w |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1bb9MwFLbGJlW8cJ8oMOYHhtqHdEns3MqENNKVdtAObaz0zXJiR6uG0qkXNPZX-Fn8Ic6Jm47CEC9ISK3U3Hxqn2P7fPE5nwl5oaMMcIXUlnQ8ZfGIO5Zkvm_JIgszjXSgMHe41_c7p_xw6A3XyFWZC2P4IZYv3LBnFOM1dvALle1ek4aCA3bSjbsAmB1wwy0AeQ5SGwF8sPkOrl6BiuEbw5wOv-Cz321Zh70BnDtgDbsRH-2wN67FbpEN7jMXgVvr-Jp6KozMCgSMJBbMYV6F7C1k79ZQbn0ptWZk1j3e5HsgrdksJb02cl6BlJVpbwM1eIlhmHIKmsjMFho3-birLnMx57Xvkm9la5lQl_PGfJY00qtfiCT_T3PeI3cWrjTdN7Z_n6zp_AGp9BbBAg_Jd6TUhmu0CJvXl4A36Dij4PHSM0DfuCfSCBPHKG5OMc6pQ2udwbFTx5vONEaaz0ZTGtMvo8l8CtfiQb1Ju-WmLhSewKLSVcbrUkIZ5JZTmSuQUEQi6ymdjSkydEwyPcFrnzNJTQrcVzhPFyy3U4qvx6Hogrj45z_ziJy2Dz7GHWuxh4WVsoBxSyWJn2ovtANXSQCLTKpIhpLzREIzZ44KUj9x0yzwfCm5L30vSJSyUztUMJyqkG2S9Xyc68eEMhUp6fJU2yrgGcDWyA1lwFSQQb9SgV8lvdLExIWhKhGGlNoVAnWL0Qa-QM0Ko1fhccEFaFQI0KZAbQombBEfCVewKnlZ2OmyMDk5xzDAwBOf-m_FkDG73TkORbtKtlYMefkAzBUhd-0q2S4NW8DghStSMtfj-VQAGAD8EPp_viOIwAOF7lclm6ZHLAuPPA-AoQO1Lsz6tyr_pcY3VLg4fvKPy9smlQ-ttnjf7b97Sm6bjFaM-3pG1meTud4Cl3aWPC_Gnh_ReoIr |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+complexity+of+the+hypervariable+region+1+%28HVR1%29+of+hepatitis+C+virus+%28HCV%29%3A+Influence+on+the+characteristics+of+the+infection+and+responses+to+interferon+alfa+therapy+in+patients+with+chronic+hepatitis+C&rft.jtitle=Journal+of+medical+virology&rft.au=Pawlotsky%2C+Jean-Michel&rft.au=Pellerin%2C+Muriel&rft.au=Bouvier%2C+Magali&rft.au=Roudot-Thoraval%2C+Fran%C3%A7oise&rft.date=1998-04-01&rft.issn=0146-6615&rft.eissn=1096-9071&rft.volume=54&rft.issue=4&rft.spage=256&rft.epage=264&rft_id=info:doi/10.1002%2F%28SICI%291096-9071%28199804%2954%3A4%3C256%3A%3AAID-JMV4%3E3.0.CO%3B2-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002__SICI_1096_9071_199804_54_4_256__AID_JMV4_3_0_CO_2_3 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon |